SmartMed Technologies in talks to partner with Indian firm for cell therapy development

SmartMed Technologies today announced that it is in advanced discussions to team up with an Indian biotech firm for the development for cell and gene therapy.

Online PR News – 04-February-2021 – YEONGDEUNGPO-GU/SEOUL – SmartMed Technologies will use an artificial intelligence based platform to create optimized media images of the development of cells and gene therapy production.

SmartMed Technologies’ Chief Technology Officer, Mr. Bayard Donovan commented on the proposed partnering with the Indian biotech firm saying "We are quite excited on how the negotiations are moving forward and this potential collaboration could be a massive opportunity that has come in terms of product development. Hopefully all goes well and our development team can seize this opportunity.”

“Both teams possess creativity and vision and this potential partnership will focus on clinical call and gene therapy development which is ground breaking in the medical world. SmartMed Technologies are looking to expand the business with both allogeneic and autologous demand for cell and gene therapies. We hope that our robust platform will enable SmartMed Technologies to rapidly implement this technology across the medical sector,” added Bayard Donovan, Chief Technology Officer of SmartMed Technologies.

About Us - SmartMed Technologies

SmartMed Technologies is a pioneering bioinformatics medical research and development company focused on delivering innovative medical products through artificial intelligence technology to combat prevalent, rare and emerging diseases.

Based in Seoul, our team collects and analyzes big data, utilizing artificial intelligence to gain insight into complex diseases such as leukemia and different cancers. Our approach centers on genome integration with high-performance computers and deep artificial intelligence learning.

With our advanced technology, we have been able to cut costs arising from industry trial-and-error procedures; with the integration of supercomputers into our work, we are able to run more comprehensive simulations, better target proteins, discover new drug compounds for a multitude of diseases, and generally increase our capacity for successful drug development.

With international recognition for our research and projects, some in collaboration with world-renowned institutions, we consistently aim to develop our understanding in the medical field through artificial intelligence and advanced clinical trials.